In recognition of all the pros and cons of the PSMA-targeted radionuclide therapies, The Prostate Cancer Foundation convened in 2017 a PSMA-Directed Radionuclide Scientific Working Group to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the future studies and clinical trials necessary for validating and optimizing the use of these. Here, FOLH1 is linked to Familial prostate cancer.